As European markets experience a lift, buoyed by hopes of lower U.S. borrowing costs and a surge in business activity, investors are turning their attention to small-cap stocks that might offer unique opportunities amidst the shifting economic landscape. In this environment, identifying promising stocks involves looking for companies with strong fundamentals and growth potential that can capitalize on these favorable conditions.

Name

Debt To Equity

Revenue Growth

Earnings Growth

Health Rating

La Forestière Equatoriale

NA

-65.30%

37.55%

★★★★★★

Flügger group

30.11%

1.55%

-30.01%

★★★★★☆

Caisse Regionale de Credit Agricole Mutuel Toulouse 31

19.46%

0.47%

7.14%

★★★★★☆

Grenobloise d’Electronique et d’Automatismes Société Anonyme

0.01%

7.01%

-1.81%

★★★★★☆

Zespól Elektrocieplowni Wroclawskich KOGENERACJA

14.04%

21.73%

17.76%

★★★★★☆

Dekpol

63.20%

11.99%

14.08%

★★★★★☆

Viohalco

93.48%

11.98%

14.19%

★★★★☆☆

ABG Sundal Collier Holding

46.02%

-6.02%

-15.62%

★★★★☆☆

Practic

NA

4.86%

6.64%

★★★★☆☆

Eurofins-Cerep

0.46%

6.80%

6.93%

★★★★☆☆

Click here to see the full list of 330 stocks from our European Undiscovered Gems With Strong Fundamentals screener.

We’re going to check out a few of the best picks from our screener tool.

Simply Wall St Value Rating: ★★★★★★

Overview: ChemoMetec A/S specializes in developing, producing, and selling analytical equipment for cell counting and analysis across the United States, Canada, Europe, and internationally with a market capitalization of DKK9.09 billion.

Operations: ChemoMetec generates revenue primarily from consumables (DKK208.76 million), instruments (DKK142.83 million), and services (DKK103.43 million).

ChemoMetec, a nimble player in the Life Sciences sector, showcases robust financial health with cash exceeding its total debt. Over the past five years, earnings have surged at an impressive 19.7% annually, though recent growth of 17.6% slightly trailed the industry average of 17.9%. The company enjoys high-quality earnings and forecasts suggest continued momentum with a projected growth rate of 17.87% per year. Additionally, ChemoMetec’s debt-to-equity ratio has improved from 0.4% to 0.2%, reflecting prudent financial management and positioning it well for future opportunities in its field.

CPSE:CHEMM Debt to Equity as at Aug 2025

CPSE:CHEMM Debt to Equity as at Aug 2025

Simply Wall St Value Rating: ★★★★★☆

Story continues